{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036395","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.777284+00:00","generated_at":"2026-06-04T08:00:25.571791+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioAtla Q4 net loss $26.9M; cash $111.5M; multiple Phase 2 readouts on track for 2Q 2024","bullets":["Net loss Q4 2023: $26.9M vs $27.6M Q4 2022; R&D expense $22.7M vs $21.9M.","Cash $111.5M at year-end 2023; expected to fund operations into 2H 2025.","CAB-CTLA-4 (BA3071) cleared DLT at 700 mg; Phase 2 monotherapy data due 2Q 2024.","CAB-ROR2-ADC (BA3021) Phase 2 melanoma/SCCHN fully enrolled; data readouts in May.","CAB-AXL-ADC (BA3011) UPS registration trial enrollment ~20 patients due April; FDA meeting 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036395","json":"https://secwatch.observer/filing/0000950170-24-036395.json","markdown":"https://secwatch.observer/filing/0000950170-24-036395.md","text":"https://secwatch.observer/filing/0000950170-24-036395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024036395/0000950170-24-036395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024036395/bcab-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:00:25.571791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2050cdde9c1bf74efea46815ef372156e270803","claim":"BioAtla, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024036395/0000950170-24-036395-index.htm","confidence":0.65,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}